Lincoln Pharmaceuticals has announced the record date for its 32nd Annual General Meeting. The company will hold the meeting on September 30, 2026, via video conferencing or other audio-visual means.

Book Closure and Record Date

The record date is set for Friday, September 11, 2026. The book closure period runs from Saturday, September 12, 2026, through Wednesday, September 30, 2026. This determines eligibility for shareholders to receive dividends if approved at the AGM.

Dividend Proposal

The company proposes a final dividend of ₹1.80 per equity share. This represents an 18% payout on the face value of ₹10. The dividend applies to the financial year ending March 31, 2026.

Payment of the final dividend is subject to approval by members at the AGM. Trusha Shah, Company Secretary and Compliance Officer, issued the intimation on August 29, 2026, pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Lincoln Pharmaceuticals Limited reported a consolidated net profit of ₹36.23 crore for the quarter ended June 30, 2026, representing a 30.90% increase compared to ₹27.68 crore in the corresponding period of FY26. The Ahmedabad-based pharmaceutical company also saw its total income rise 19.02% to ₹201.55 crore, driven by robust performance across key therapeutic segments including cardiac, diabetic, dermatology, and ENT.

The Board of Directors approved the unaudited standalone and consolidated financial results on August 13, 2026. The results were reviewed by Samir M. Shah & Associates, Chartered Accountants, in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial performance

Revenue from operations stood at ₹177.28 crore for the quarter, up from ₹154.07 crore in Q1FY26. EBITDA expanded 32.29% to ₹51.70 crore, outpacing revenue growth and indicating improved operational leverage. Profit before tax rose 34.36% to ₹47.55 crore.

Earnings per share rose to ₹18.09 from ₹13.82 in Q1FY26. For the full fiscal year FY26, the company had reported a net profit of ₹87.89 crore, a 6.74% growth over FY25.

What the numbers show

EBITDA grew at a faster pace than total income in Q1FY27, expanding 32.29% against a 19.02% rise in topline figures. This divergence points to effective cost management or a favorable product mix shift during the quarter, enhancing operating margins despite moderate revenue acceleration.

Strategic outlook

Lincoln Pharmaceuticals remains net-debt free and plans to achieve annual revenue growth of 15-18%, targeting ₹1,000 crore in revenue over the next three years. The company plans to expand its export footprint from over 60 countries to 90 countries within two to three years, leveraging recent approvals from EU GMP, TGA Australia, and entry into the Canadian market.

CRISIL Ratings has reaffirmed its 'CRISIL A/Stable/CRISIL A1' ratings on the company's bank facilities, citing strong promoter experience and a healthy financial profile. Foreign Institutional Investors held a stake of 4.60% as on June 30, 2026.